The buyers or most likely investors will arrive soon enough and in numbers once a suitable deal is done with Amgen and a clear funded pathway to commercialisation and revenue can be seen and with a giant of the pharma industry as a cornerstone investor. When the deal is done nothing will be the same again for many reasons.
